Effects of Low Dose Naltrexone in Fibromyalgia

Completed · Not applicable · Has a placebo group

Conditions studied: Fibromyalgia, Persian Gulf Syndrome

In brief

Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural pain-reducing systems. In this study, we will administer both LDN and placebo to a small group of individuals with Fibromyalgia and Gulf War Syndrome, both Chronic Multisymptom Illnesses, to assess the drug's efficacy in treating the condition.

Key facts

Study ID

NCT00568555

Run by

Stanford University

People needed

53

Starts

2007-06-01

Expected to finish

2010-01-01

Last updated by the study team

2015-10-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Currently suffering from moderate to severe Fibromyalgia or symptoms of Gulf War Syndrome Age 18-65. Not taking any opioid analgesic Not pregnant or planning to become pregnant.

You may not qualify if…

• Any known allergy to naltrexone or naloxone. Actual or planned pregnancy.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.